Eileen´s Final Report

The following tables are arranged according the format presented in the file HbA1c Bariatric Data Tables.docx. The name of the variables is changed to make the coding process easier nevertheless they remain understandable when compared to the .docx file.

Splitting Population for the Study

For the goal of this study the following subsettings were made:

1. Only patients who underwent Sleeve Gastrectomy or RYGB were selected.
2. Group then was split into degree of control of the disease (DM2) understood as follows:

• Controlled : \(HbA1c \leq 6\)
• Elevated : \(6 < HbA1c \leq 8.5\)
• Super Elevated : \(HbA1c > 8.5\)

Once this preprocess is done we proceed with the analysis.

Charactersitics of Study Population

	Controlled	Elevated	Super-Elevated	P-value between all 3 groups
age	44.7	50.4	45.8	0.0
malePerc	17.300	25.100	31.700	0.019
bmi	46.000	46.200	47.100	0.827
hba1c	5.6	6.8	9.9	0.0
racePerc	83.800	82.100	73.200	0.233
insurancePerc	95.100	94.700	97.600	0.737
smokingPerc	68.400	70.000	97.600	0.058
rygbPerc	26.9	36.7	65.9	0.0
sleevePerc	73.1	63.3	34.1	0.0
priorSxPerc	66.500	0.000	63.400	0.264
chemoPerc	4.900	8.200	2.400	0.176
radioPerc	3.000	6.800	0.000	0.037
steroidsPerc	14.60	11.60	12.20	0.59
immunoPerc	4.700	3.400	4.900	0.748
biologicsPerc	2.200	1.400	2.400	0.804
anticoagPerc	4.700	6.300	4.900	0.705

Pre-operative Vital Signs and Labs

	Controlled	Elevated	Super-Elevated	P-value between all 3 groups
hba1c0Mean	5.5	6.8	9.2	0.0
sbp0Mean	132.400	132.100	137.100	0.131
dbp0Mean	81.600	79.000	82.200	0.004
weight0Mean	124.900	128.700	129.500	0.149

Group Analysis of variables showing statistically significant differences for PreOp vitals and labs

HbA1c

## 
##  Pairwise comparisons using Wilcoxon rank sum test with continuity correction 
## 
## data:  dat$hba1c_preop and dat$group 
## 
##               controlled elevated
## elevated      <2e-16     -       
## superElevated <2e-16     <2e-16  
## 
## P value adjustment method: BH

Dyastolic Blood Pressure

## 
##  Pairwise comparisons using Wilcoxon rank sum test with continuity correction 
## 
## data:  dat$preop_diast_bp and dat$group 
## 
##               controlled elevated
## elevated      0.0053     -       
## superElevated 0.6604     0.0430  
## 
## P value adjustment method: BH

Weight

## 
##  Pairwise comparisons using Wilcoxon rank sum test with continuity correction 
## 
## data:  dat$preop_weight and dat$group 
## 
##               controlled elevated
## elevated      0.27       -       
## superElevated 0.30       0.69    
## 
## P value adjustment method: BH

Pre-operative Comorbidities

	Controlled	Elevated	Super-Elevated	P-value between all 3 groups
htnPerc	52.7	75.4	90.2	0.0
dmPerc	11.3	61.8	97.6	0.0
hypoPerc	0.300	1.000	4.900	0.008
gerdPerc	58.800	60.400	63.400	0.819
osaPerc	43.100	48.800	34.100	0.166
hiatalPerc	44.000	36.200	24.400	0.021
cadPerc	3.600	6.800	14.600	0.007
chfPerc	5.800	9.700	4.900	0.186
strokePerc	1.90	2.90	0.00	0.46
crdPerc	6.900	12.100	9.800	0.106
lipidemiaPerc	41.5	63.8	80.5	0.0
osteoPerc	55.200	58.500	48.800	0.483
deprePerc	42.900	45.900	46.300	0.748
homeOxPerc	0.500	1.000	4.900	0.029

Complications at 1-Month

	Controlled	Elevated	Super-Elevated	P-value between all 3 groups
los1Mean	2.10	2.40	2.40	0.01
erMonthPerc	8.200	10.600	9.800	0.631
clinicMonthPerc	0.3	0.0	0.0	NA
readmMonthPerc	5.800	7.200	9.800	0.731
ssiMonthPerc	3.300	2.400	0.000	0.505
hapMonthPerc	0.300	0.000	0.000	0.711
bsiMonthPerc	0.300	0.000	0.000	0.711
utiMonthPerc	1.100	0.500	0.000	0.613
cdiMonthPerc	0.300	0.000	0.000	0.711
sepsisMonthPerc	0.300	0.500	0.000	0.852
ileusMonthPerc	2.500	0.500	0.000	0.566
svaMonthPerc	1.60	3.40	0.00	0.24
ciMonthPerc	0	0	0	NA
vteMonthPerc	0.500	0.500	0.000	0.892
hemMonthPerc	0.300	1.400	0.000	0.214
urMonthPerc	3.300	8.200	4.900	0.036
akiMonthPerc	0.30	1.00	2.40	0.21
cdscMonthPerc	11.8	14.0	14.6	0.7
rtorMonthPerc	1.10	2.40	2.40	0.45
notRtorMonthPerc	0.300	0.500	0.000	0.852
mortMonthPerc	0.500	0.000	0.000	0.505

Group Analysis of variables showing statistically significant differences for complications at 1-Month

Mean of Length of Stay

## 
##  Pairwise comparisons using Wilcoxon rank sum test with continuity correction 
## 
## data:  dat$thirty_los and dat$group 
## 
##               controlled elevated
## elevated      0.024      -       
## superElevated 0.077      0.568   
## 
## P value adjustment method: BH

Percentage of urinary retention

## 
##  Pairwise comparisons using Wilcoxon rank sum test with continuity correction 
## 
## data:  dat$thirty_ur and dat$group 
## 
##               controlled elevated
## elevated      0.031      -       
## superElevated 0.601      0.601   
## 
## P value adjustment method: BH

Amount of patients with available data in variables per cohort

For this section it is important to remember that ther are a total of 738 patients contained in this data set.

	1-Month	3-Months	6-Months	1-Year
hba1cAvail	197	448	391	282
weightAvail	642	579	474	349
sbpAvail	619	567	471	345
dbpAvail	617	564	466	340
hdlAvail	192	447	393	281
ldlAvail	192	446	392	281
cholAvail	195	449	394	281
triglycAvail	195	449	392	281
bmiAvail	Data	not	available	-__-
ibwAvail	638	578	475	18
ebwlAvail	641	577	474	348

Vital Signs at 2 Weeks

	Controlled	Elevated	Super-Elevated	P-value between all 3 groups
sbpWeeks	114.6	117.7	127.0	0.029
dbpWeeks	74.4	72.8	78.5	0.397

Group analysis of systolic blood pressure at 2 weeks postOp

## 
##  Pairwise comparisons using Wilcoxon rank sum test with continuity correction 
## 
## data:  dat$weeks_sbp and dat$group 
## 
##               controlled elevated
## elevated      0.120      -       
## superElevated 0.066      0.176   
## 
## P value adjustment method: BH

Vital signs at 1-Month postOp

	Controlled	Elevated	Super-Elevated	P-value between all 3 groups
hba1c1Median	5.4	6.2	8.0	0.0
sbp1Mean	123.80	129.30	129.40	0.04
dbp1Mean	79.200	79.300	79.700	0.864
weight1Mean	111.100	114.900	114.900	0.199
ibw1Mean	63.800	71.700	68.100	0.023
ebwl1Mean	27.600	26.800	26.400	0.981
ldl1Mean	97.100	101.100	94.200	0.816
hdl1Mean	40.800	42.300	38.900	0.624
chol1Mean	156.600	169.000	153.100	0.104
trig1Mean	108.9	140.5	140.0	0.0
crp1Mean	8.000	8.000	7.600	0.999

Group analysis of variables where there are statistically significant differents among groups.

HbA1c

## 
##  Pairwise comparisons using Wilcoxon rank sum test with continuity correction 
## 
## data:  dat$one_hba1c and dat$group 
## 
##               controlled elevated
## elevated      4.8e-11    -       
## superElevated 1.2e-05    0.0013  
## 
## P value adjustment method: BH

SBP

## 
##  Pairwise comparisons using Wilcoxon rank sum test with continuity correction 
## 
## data:  dat$one_sbp and dat$group 
## 
##               controlled elevated
## elevated      0.037      -       
## superElevated 0.538      0.730   
## 
## P value adjustment method: BH

Weight

## 
##  Pairwise comparisons using Wilcoxon rank sum test with continuity correction 
## 
## data:  dat$one_weight and dat$group 
## 
##               controlled elevated
## elevated      0.28       -       
## superElevated 0.51       0.96    
## 
## P value adjustment method: BH

IBW

## 
##  Pairwise comparisons using Wilcoxon rank sum test with continuity correction 
## 
## data:  dat$one_ibw and dat$group 
## 
##               controlled elevated
## elevated      0.018      -       
## superElevated 0.569      0.569   
## 
## P value adjustment method: BH

Triglycerides

## 
##  Pairwise comparisons using Wilcoxon rank sum test with continuity correction 
## 
## data:  dat$one_triglycerids and dat$group 
## 
##               controlled elevated
## elevated      0.0022     -       
## superElevated 0.0101     0.4148  
## 
## P value adjustment method: BH

Vital signs at 3-Months postOp

	Controlled	Elevated	Super-Elevated	P-value between all 3 groups
hba1c3Median	5.3	5.9	6.7	0.0
sbp3Mean	121.200	126.800	128.600	0.007
dbp3Mean	77.10	78.10	79.00	0.23
weight3Mean	104.500	108.900	112.900	0.027
ibw3Mean	68.30	70.50	69.00	0.01
ebwl3Mean	37.80	37.70	34.90	0.15
ldl3Mean	104.800	102.700	95.300	0.449
hdl3Mean	47.300	48.100	41.400	0.034
chol3Mean	168.300	169.500	160.600	0.354
trig3Mean	106.4	126.9	134.5	0.0
crp3Mean	5.800	8.600	6.800	0.396

Group analysis of variables where there are statistically significant differents among groups at 3-months.

HbA1c

## 
##  Pairwise comparisons using Wilcoxon rank sum test with continuity correction 
## 
## data:  dat$three_hba1c and dat$group 
## 
##               controlled elevated
## elevated      < 2e-16    -       
## superElevated 1.8e-10    0.0033  
## 
## P value adjustment method: BH

SBP

## 
##  Pairwise comparisons using Wilcoxon rank sum test with continuity correction 
## 
## data:  dat$three_sbp and dat$group 
## 
##               controlled elevated
## elevated      0.026      -       
## superElevated 0.037      0.614   
## 
## P value adjustment method: BH

Weight

## 
##  Pairwise comparisons using Wilcoxon rank sum test with continuity correction 
## 
## data:  dat$three_weight and dat$group 
## 
##               controlled elevated
## elevated      0.092      -       
## superElevated 0.072      0.218   
## 
## P value adjustment method: BH

IBW

## 
##  Pairwise comparisons using Wilcoxon rank sum test with continuity correction 
## 
## data:  dat$three_ibw and dat$group 
## 
##               controlled elevated
## elevated      0.0077     -       
## superElevated 0.4551     0.6435  
## 
## P value adjustment method: BH

HDL

## 
##  Pairwise comparisons using Wilcoxon rank sum test with continuity correction 
## 
## data:  dat$three_hdl and dat$group 
## 
##               controlled elevated
## elevated      0.723      -       
## superElevated 0.025      0.041   
## 
## P value adjustment method: BH

Triglycerides

## 
##  Pairwise comparisons using Wilcoxon rank sum test with continuity correction 
## 
## data:  dat$three_triglyced and dat$group 
## 
##               controlled elevated
## elevated      0.00033    -       
## superElevated 0.01283    0.45995 
## 
## P value adjustment method: BH

Vital signs at 6-Months postOp

	Controlled	Elevated	Super-Elevated	P-value between all 3 groups
hba1c6Median	5.3	5.7	6.2	0.0
sbp6Mean	122.700	125.900	131.600	0.107
dbp6Mean	77.500	76.900	76.900	0.697
weight6Mean	95.700	102.200	105.400	0.015
ibw6Mean	68.300	70.900	70.100	0.011
ebwl6Mean	53.800	50.200	47.500	0.055
ldl6Mean	101.200	103.600	97.800	0.587
hdl6Mean	52.300	52.300	44.500	0.026
chol6Mean	169.000	175.900	167.600	0.278
trig6Mean	103.2	122.6	148.9	0.0
crp6Mean	5.100	5.300	4.300	0.367

Group analysis of variables where there are statistically significant differents among groups at 6-months.

HbA1c

## 
##  Pairwise comparisons using Wilcoxon rank sum test with continuity correction 
## 
## data:  dat$six_hba1c and dat$group 
## 
##               controlled elevated
## elevated      < 2e-16    -       
## superElevated 1.5e-07    0.032   
## 
## P value adjustment method: BH

Weight

## 
##  Pairwise comparisons using Wilcoxon rank sum test with continuity correction 
## 
## data:  dat$six_weight and dat$group 
## 
##               controlled elevated
## elevated      0.052      -       
## superElevated 0.052      0.264   
## 
## P value adjustment method: BH

IBW

## 
##  Pairwise comparisons using Wilcoxon rank sum test with continuity correction 
## 
## data:  dat$six_ibw and dat$group 
## 
##               controlled elevated
## elevated      0.0097     -       
## superElevated 0.3367     0.7708  
## 
## P value adjustment method: BH

EBWL

## 
##  Pairwise comparisons using Wilcoxon rank sum test with continuity correction 
## 
## data:  dat$six_ebwl and dat$group 
## 
##               controlled elevated
## elevated      0.15       -       
## superElevated 0.12       0.29    
## 
## P value adjustment method: BH

HDL

## 
##  Pairwise comparisons using Wilcoxon rank sum test with continuity correction 
## 
## data:  dat$six_hdl and dat$group 
## 
##               controlled elevated
## elevated      0.567      -       
## superElevated 0.022      0.017   
## 
## P value adjustment method: BH

Triglycerides

## 
##  Pairwise comparisons using Wilcoxon rank sum test with continuity correction 
## 
## data:  dat$six_triglyced and dat$group 
## 
##               controlled elevated
## elevated      0.002      -       
## superElevated 0.002      0.039   
## 
## P value adjustment method: BH

Vital signs at 12-Months postOp

	Controlled	Elevated	Super-Elevated	P-value between all 3 groups
hba1c12Median	5.2	5.6	6.6	0.0
sbp12Mean	122.500	126.100	128.800	0.564
dbp12Mean	77.200	76.000	79.800	0.264
weight12Mean	91.100	97.400	95.800	0.188
ibw12Mean	9.300	1.000	1.000	0.819
ebwl12Mean	61.300	57.400	57.400	0.467
ldl12Mean	94.600	105.100	109.400	0.101
hdl12Mean	61.300	59.300	51.200	0.011
chol12Mean	171.100	182.300	174.000	0.245
trig12Mean	97.200	105.700	108.100	0.032
crp12Mean	3.400	4.300	2.400	0.025

Group analysis of variables where there are statistically significant differents among groups at 12-months.

hba1c

## 
##  Pairwise comparisons using Wilcoxon rank sum test with continuity correction 
## 
## data:  dat$year_hba1c and dat$group 
## 
##               controlled elevated
## elevated      1.6e-14    -       
## superElevated 1.2e-07    0.0079  
## 
## P value adjustment method: BH

HDL

## 
##  Pairwise comparisons using Wilcoxon rank sum test with continuity correction 
## 
## data:  dat$year_hdl and dat$group 
## 
##               controlled elevated
## elevated      0.4270     -       
## superElevated 0.0083     0.0204  
## 
## P value adjustment method: BH

Triglycerides

## 
##  Pairwise comparisons using Wilcoxon rank sum test with continuity correction 
## 
## data:  dat$year_triglyced and dat$group 
## 
##               controlled elevated
## elevated      0.053      -       
## superElevated 0.179      0.693   
## 
## P value adjustment method: BH

CRP

## 
##  Pairwise comparisons using Wilcoxon rank sum test with continuity correction 
## 
## data:  dat$year_crp and dat$group 
## 
##               controlled elevated
## elevated      0.052      -       
## superElevated 0.377      0.073   
## 
## P value adjustment method: BH

Resolution of Comorbidities